PCI Before TAVR? In Older CAD Patients, Deferral May Be the Best Approach

Why It Matters

Deferring PCI can spare frail, older patients unnecessary invasive procedures and bleeding risk, potentially reshaping treatment pathways for co‑existing coronary disease and aortic stenosis. This evidence supports a more conservative, patient‑centered approach that may lower costs and improve recovery.

Key Takeaways

• PCI before TAVR shows non‑inferior outcomes
• Major bleeding higher with pre‑TAVR PCI
• Only 11% needed PCI after TAVR deferral
• Elderly high‑risk patients benefit from watch‑and‑wait
• Study based on 466 Dutch patients, median age 81

Pulse Analysis

Transcatheter aortic valve replacement has become the preferred therapy for severe aortic stenosis in patients deemed too high‑risk for open‑heart surgery. Because many of these individuals also carry coronary artery disease, clinicians traditionally perform percutaneous coronary intervention before valve implantation to address ischemia and reduce peri‑procedural complications. However, adding PCI introduces dual antiplatelet therapy, increases procedural time, and raises the likelihood of bleeding—factors that can be especially detrimental in octogenarians with multiple comorbidities.

The PRO‑TAVI trial challenges this conventional sequence by randomizing 466 elderly Dutch patients to either pre‑TAVR PCI or a strategy of deferring PCI unless symptoms persisted after valve implantation. The study’s primary composite endpoint at one year was virtually identical between groups, and the deferral arm experienced a modest reduction in major bleeding events. Notably, only a small fraction—11%—of patients in the deferred cohort eventually required coronary revascularization, suggesting that many elderly patients may never need PCI if the aortic valve issue is addressed first. These findings provide robust, randomized evidence that a watch‑and‑wait approach does not compromise safety or efficacy in this high‑risk population.

If incorporated into clinical guidelines, the deferral strategy could transform heart‑team decision‑making, emphasizing individualized risk assessment over routine pre‑emptive revascularization. Potential benefits include shorter hospital stays, reduced exposure to antiplatelet agents, and lower overall procedural costs. Nonetheless, the trial’s focus on an older, predominantly male European cohort means further research is needed to confirm applicability across diverse demographics and younger patients. As the field moves toward value‑based care, the PRO‑TAVI results underscore the importance of tailoring invasive therapies to the specific risk profile of each patient, rather than adhering to a one‑size‑fits‑all protocol.